Nektar Therapeutics (NKTR) Non-Current Debt (2012 - 2020)
Nektar Therapeutics (NKTR) posted quarterly Non-Current Debt of $254.8 million for Q1 2020, up 3.0% year-over-year from $247.4 million in Q2 2019, and up 2.64% quarter-over-quarter from $248.3 million in Q3 2019.
Nektar Therapeutics (NKTR) Non-Current Debt (2012 - 2020) Analysis & Trends
Nektar Therapeutics' Non-Current Debt history runs 9 years deep, the most recent figure standing at $254.8 million for Q1 2020.
- In Q1 2020, Non-Current Debt rose 3.0% year-over-year to $254.8 million; the TTM figure through Mar 2020 stood at $254.8 million (up 3.0% YoY), while the FY2018 annual figure was $247.0 million, up 0.71% from the prior year.
- Non-Current Debt for Q1 2020 stood at $254.8 million, up from $248.3 million in the prior quarter.
- The five-year high for Non-Current Debt was $254.8 million in Q1 2020, with the low at $242.1 million in Q1 2016.
- The 5-year median for Non-Current Debt is $245.4 million (2017), against an average of $245.8 million.
- The sharpest annual moves came in 2016 and 2019: Non-Current Debt jumped 94.05% in 2016, then rose 0.71% in 2019.
- Nektar Therapeutics' Non-Current Debt stood at $243.5 million in 2016, then climbed by 0.72% to $245.2 million in 2017, then climbed by 0.71% to $247.0 million in 2018, then rose by 0.53% to $248.3 million in 2019, then increased by 2.64% to $254.8 million in 2020.
- Business Quant data shows NKTR's Non-Current Debt at $254.8 million in Q1 2020, $248.3 million in Q3 2019, and $247.8 million in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 254.80 Mn |
| Sep 30, 2019 | 248.26 Mn |
| Jun 30, 2019 | 247.82 Mn |
| Mar 31, 2019 | 247.39 Mn |
| Dec 31, 2018 | 246.95 Mn |
| Sep 30, 2018 | 246.51 Mn |
| Jun 30, 2018 | 246.08 Mn |
| Mar 31, 2018 | 245.64 Mn |
| Dec 31, 2017 | 245.21 Mn |
| Sep 30, 2017 | 244.77 Mn |
| Jun 30, 2017 | 244.34 Mn |
| Mar 31, 2017 | 243.90 Mn |
| Dec 31, 2016 | 243.46 Mn |
| Sep 30, 2016 | 243.00 Mn |
| Jun 30, 2016 | 242.57 Mn |
| Mar 31, 2016 | 242.13 Mn |
| Dec 31, 2015 | 241.70 Mn |
| Jun 30, 2015 | 125.00 Mn |
| Mar 31, 2015 | 125.00 Mn |
| Dec 31, 2014 | 125.00 Mn |